- FOQUS scans the whole brain for emboli in 40 seconds and can be performed by a single nurse in physician offices, diagnostic centers or hospitals.
- Clearance follows the CE Mark for SONAS® stroke detection and first human uses in the Netherlands and UK.
- U.S. commercial launch to begin early 2027.
SAN DIEGO, Nov. 19, 2026 /PRNewswire/ — BURL Concepts, a private medtech company developing an automated and affordable test for evaluating cerebral blood flow and rapid detection of emboli, announced today that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the FOQUS™ ultrasound system, powered by SONAS®, a medical ultrasound device indicated for use for measuring the occurrence of transient embolic signals in the brain blood stream.
FOQUS is a portable, automated transcranial ultrasound system that monitors the entire brain for the appearance of emboli. A standard Patent Foramen Ovale (PFO) ‘bubble test’ will be the first clinical application of FOQUS when an air bubble solution is administered intravenously and acoustic signals generated by air bubbles are detected as they pass through the brain’s circulation. The detection of such an acoustic signal helps physicians identify the presence of a Right-To-Left Shunt (RLS), which is commonly caused a PFO, or a hole between the left and right atria of the heart that failed to close after birth. Approximately 40 to 50% of patients with cryptogenic stroke have a PFO.
Unlike traditional transcranial Doppler (TCD), which requires a skilled operator to locate the temporal bone window and identify a specific vessel segment, FOQUS uses low-energy, low-frequency ultrasound to penetrate the skull and evaluate the whole brain, detecting acoustic signals from the entire circulation, including both macro and microvasculature. The test is fully automated and delivers instant, objective, quantitative data, including both an immediate results display as well as a comprehensive results report indicating whether embolic signals were detected. Because it does not require a cardiologist or anesthesiologist, rapid PFO testing can be performed in any location.
“Identifying a PFO in a patient who has had a cryptogenic stroke is a critical step toward preventing the next one. FOQUS gives us a simple, objective test that evaluates the whole brain without the need to find a specific acoustic window or vessel. FDA clearance means physicians in the U.S. can bring FOQUS to more patients, sooner. It has the potential to disrupt the way we currently diagnose PFOs,” said Matthew J. Price, M.D., Professor of Medicine and Director, Cardiac Catheterization Laboratory, Scripps Clinic, La Jolla.
“FOQUS makes screening quick and accessible: a test of about five minutes that can be performed in virtually any location, without specialized ultrasound skills. For the first time, a PFO screening test can be broadly available, helping to identify patients earlier and reduce the risk of disabling strokes,” said Thilo Hoelscher, M.D., Chief Medical Officer of BURL Concepts.
“FDA clearance represents a defining milestone for BURL Concepts and an important step toward making advanced transcranial ultrasound testing more accessible,” said Peter van der Sluis, Chief Executive Officer of BURL Concepts. “Our goal is not simply to make testing faster; it is to remove practical barriers that limit where and how efficiently patients can be evaluated. Similar to the expansion of cardiac arrhythmia monitoring into outpatient settings, we believe FOQUS has the potential to broaden access to transcranial testing. With regulatory clearance now achieved, our focus turns to our U.S. commercial launch.”
FOQUS is also currently being used in the Netherlands and the United Kingdom, where early experience has included the detection of embolic signals associated with right-to-left shunting, and additional clinical trials in the United States and Europe are underway. BURL Concepts is preparing for its initial U.S. commercial launch in early 2027, with a focus on cardiology practices and outpatient diagnostic centers.
About FOQUS
FOQUS is a portable, automated transcranial ultrasound system powered by SONAS technology. The system combines a battery-powered console with a headset to measure the occurrence of transient embolic signals in the cerebral circulation. FOQUS is designed to simplify testing and support broader clinical access, including during evaluations of suspected right-to-left shunting. The system received FDA 510(k) clearance in November 2026. Learn more at www.foqus.burlconcepts.com.
About BURL Concepts
BURL Concepts, Inc. is a San Diego-based medical technology company developing noninvasive ultrasound technologies to make cerebral assessment faster, simpler, and more accessible. Through its SONAS technology platform and FOQUS system, BURL Concepts aims to expand access to transcranial ultrasound testing across hospital and outpatient settings. For more information, visit www.burlconcepts.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/burl-concepts-announces-fda-510k-clearance-for-foqus-ultrasound-system-for-rapid-automated-patent-foramen-ovale-pfo-screening-302944716.html
SOURCE BURL Concepts
